326859-36-3
Chemical Structure
Fontolizumab
Synonym(s): HuZAF; Anti-Human IFNG Recombinant Antibody
- CAS No.: 326859-36-3
- Formula:N/A
- Molecular Weight:(144.8 kDa)
IUPAC Name: 2-(butoxy-d9)acetic acid
SMILES: [Fontolizumab]
Biological Activity: Fontolizumab (HuZAF) is a human monoclonal antibody targeting interferon γ (IFN-γ). Fontolizumab binds specifically and with high affinity to secreted IFN-γ, neutralizes its activity, blocks receptor binding, and inhibits downstream signal transduction and the expression of IFNγ-responsive genes. Fontolizumab reduces serum C-reactive protein levels, inhibits the expression of IL-1α, IL-1β and IL-12Rβ2, and decreases the number of IFNγ-producing T cells in activated peripheral blood mononuclear cells. Fontolizumab can be used in research related to Crohn's disease[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Fontolizumab | 97.18% | Fontolizumab (HuZAF) is a human monoclonal antibody targeting interferon γ (IFN-γ). Fontolizumab binds specifically and with high affinity to secreted IFN-γ, neutralizes its activity, blocks receptor binding, and inhibits downstream signal transduction and the expression of IFNγ-responsive genes. Fontolizumab reduces serum C-reactive protein levels, inhibits the expression of IL-1α, IL-1β and IL-12Rβ2, and decreases the number of IFNγ-producing T cells in activated peripheral blood mononuclear cells. Fontolizumab can be used in research related to Crohn's disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Hommes DW, et al. Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease. Gut. 2006 Aug;55(8):1131-7. [Content Brief]
- [2]. Reinisch W, et al. A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease. Gut. 2006 Aug;55(8):1138-44. [Content Brief]
- [3]. Reinisch W, et al. Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflammatory bowel diseases. 2010 Feb;16(2):233-42. [Content Brief]
- [4]. Hommes D, Mikhailova T, Stoinov S, et al. Fontolizumab (HuZaf), a humanized anti-IFN-gamma antibody, has clinical activity and excellent tolerability in moderate to severe Crohn's disease [abstract]. Gastroenterology. 2004;127(1):332.
- [5]. Haider AS, et al. Insights into gene modulation by therapeutic TNF and IFNgamma antibodies: TNF regulates IFNgamma production by T cells and TNF-regulated genes linked to psoriasis transcriptome. The Journal of investigative dermatology. 2008 Mar;128(3):655-66. [Content Brief]
